𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Randomized double-blind, placebo-controlled multi-center trial on molecular hydrogen water in Parkinson disease

✍ Scribed by Yoritaka, A.; Oyama, G.; Shimo, Y.; Hatano, T.; Ando, M.; Hattori, N.

Book ID
123272597
Publisher
Elsevier Science
Year
2013
Tongue
English
Weight
58 KB
Volume
333
Category
Article
ISSN
0022-510X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A randomized, double-blind, placebo-cont
A randomized, double-blind, placebo-controlled trial of levetiracetam for dyskinesia in Parkinson's disease
✍ Kitty K. Wong; Jane E. Alty; Amanda G. Goy; Sanjay Raghav; David C. Reutens; Pet 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 565 KB

## Abstract ## Background: This randomized double blind, placebo‐controlled crossover study investigated the antidyskinetic effects of levetiracetam in Parkinson's disease. ## Methods: Sixteen participants with levodopa‐induced dyskinesia were enrolled. Hourly videotaped dyskinesia assessments s

A randomized, double-blind, placebo-cont
A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients
✍ Fabrizio Stocchi; Rupam Borgohain; Marco Onofrj; Anthony H.V. Schapira; Mohit Bh 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 446 KB 👁 2 views

## Abstract Safinamide is an α‐aminoamide with both dopaminergic and nondopaminergic mechanisms of action evaluated as an add‐on to dopamine agonist (DA) therapy in early‐stage PD. In this 24‐week, double‐blind study, patients with early PD receiving a stable dose of a single DA were randomized to